Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745826 | 0.99 | ALDH1A1 (0.46) | ALDH1A1PKMSMN1; SMN2HSD17B10SLC1A2 | |
| SCHEMBL177980 | 0.87 | ALDH1A1 (0.48) | ALDH1A1PKMSMN1; SMN2HSD17B10SLC1A2 | |
| SCHEMBL10340551 | 0.87 | ALDH1A1 (0.43) | ALDH1A1PKMSMN1; SMN2HSD17B10SLC1A2 | |
| SCHEMBL29120327 | 0.83 | ALDH1A1 (0.43) | ALDH1A1PKMSMN1; SMN2HSD17B10EHMT2 | |
| SCHEMBL17668001 | 0.81 | MME (0.36) | ALDH1A1SMN1; SMN2HSD17B10HPGDMAPT | |
| SCHEMBL29139350 | 0.81 | ALDH1A1 (0.42) | ALDH1A1PKMSMN1; SMN2HSD17B10EHMT2 | |
| SCHEMBL44725 | 0.80 | ALDH1A1 (0.50) | ALDH1A1PKMSMN1; SMN2HSD17B10SLC1A2 | |
| Hydrogen Sulfide SCHEMBL20305480 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PKMHSD17B10HPGDEHMT2 | |
| SCHEMBL508633 | 0.79 | SMN1; SMN2 (0.39) | ALDH1A1PKMSMN1; SMN2HSD17B10SLC1A2 | |
| SCHEMBL616908 | 0.78 | ALDH1A1 (0.54) | ALDH1A1PKMSMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | claimed |
| EP-3311846-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2018-04-25 | — | — | EP | claimed |
| EP-3188761-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016036861-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | claimed |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-03 | — | — | US | claimed |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| US-10603388-B2 | Methods for formulating antibody drug conjugate compositions | IMMUNOGEN, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3311846-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | ImmunoGen, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170348428-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603388-B2 | Methods for formulating antibody drug conjugate compositions | FCGRT, FCGR1A, FCGR3B | ALDH1A1 482/4885PKM 3996/4885SMN1; SMN2 794/4885 |
| US-20160058884-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGR1A, FCGR3B, FCGRT | ALDH1A1 521/4885PKM 3941/4885SMN1; SMN2 737/4885 |
| US-20170348428-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGRT, FCGR1A, FCGR3B | ALDH1A1 482/4885PKM 3996/4885SMN1; SMN2 794/4885 |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGRT, FCGR1A, FCGR3B | ALDH1A1 482/4885PKM 3996/4885SMN1; SMN2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.